Drug Profile
Research programme: anti-midkine antibodies - Cellmid
Alternative Names: CAB 101; CAB 102; Hu91- Cellmid; IP10; IP13; IP14; IP9Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Lyramid
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Monoclonal antibodies
- Mechanism of Action MDK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation
Most Recent Events
- 23 Feb 2023 Anti-midkine antibodies are still in preclinical trials for Inflammation in Australia (Roquefort Therapeutics website, February 2023)
- 23 Feb 2023 Anti-midkine antibodies are still in preclinical trials for Cancer in Australia (Roquefort Therapeutics website, February 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)